AbbVie Inc (ABBV)vsHCW Biologics Inc (HCWB)
ABBV
AbbVie Inc
$294.90
+3.09%
HEALTHCARE · Cap: $521.11B
HCWB
HCW Biologics Inc
$1.08
-6.09%
HEALTHCARE · Cap: $2.57M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 982076% more annual revenue ($66.01B vs $6.72M). ABBV leads profitability with a 15.7% profit margin vs -83.1%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
HCWB
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$294.90
$138.06 premium
Intrinsic value data unavailable for HCWB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 1970.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -28.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : HCWB
The strongest argument for HCWB centers on Price/Book, Revenue Growth. Revenue growth of 1970.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : HCWB
The primary concerns for HCWB are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a mature stock while HCWB is a hypergrowth play — different risk/reward profiles.
HCWB carries more volatility with a beta of 2.27 — expect wider price swings.
HCWB is growing revenue faster at 1970.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 41/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
HCW Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
HCW Biologics Inc is a forward-thinking biotechnology company focused on pioneering immunotherapies and vaccine technologies to tackle pressing health issues such as cancer and infectious diseases. Utilizing its proprietary platforms to amplify immune responses, HCW Biologics is actively expanding a promising pipeline of clinical candidates poised to make significant impacts in patient care. With a keen commitment to strategic partnerships and addressing urgent medical needs, the company aims to establish itself as a competitive force in the biotechnology landscape, presenting compelling investment opportunities that align with the evolving dynamics of the healthcare sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?